Stattic

For research use only. Not for use in humans.

目录号：S7024

Stattic Chemical Structure

CAS No. 19983-44-9

Stattic 是第一个非肽类STAT3小分子抑制剂，有效抑制STAT3激活和核易位，IC50为5.1 μM，其作用于STAT3的选择性远高于STAT1。Stattic 可诱导凋亡。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 730.64 现货
RMB 901.23 现货
RMB 1392.12 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的Stattic发表文献123篇：

产品安全说明书

STAT抑制剂选择性比较

生物活性

产品描述 Stattic 是第一个非肽类STAT3小分子抑制剂，有效抑制STAT3激活和核易位，IC50为5.1 μM，其作用于STAT3的选择性远高于STAT1。Stattic 可诱导凋亡。
特性 Stattic是第一个非肽类小分子，抑制STAT3 SH2结构域的功能，无论在体外STAT3磷酸化状态。
靶点
STAT3 [1]
(Cell-free assay)
5.1 μM
体外研究

Stattic抑制gp130受体衍生的含磷酸化酪氨酸的肽结合到STAT3 SH2结构域，这种作用存在强烈的温度依赖性。Stattic对酪氨酸磷酸化的肽结合到酪氨酸激酶Lck的SH2结构域只有很微弱的作用效果。Stattic不抑制其他两个二聚体转录因子(c-Myc/Max 和 Jun/Jun)的二聚化。Stattic抑制荧光素标记的磷酸化肽段结合到STAT1和STAT5b的SH2域。Stattic浓度为10 μM，选择性抑制DNA与STAT3二聚体结合。Stattic抑制STAT3在Tyr705位点磷酸化，而对STAT1在Tyr701(HepG2细胞)位点磷酸化或 JAK1, JAK2, 和c-Src(MDA-MB-231和MDA-MB-235S细胞)磷酸化几乎没有抑制效果。Stattic增加STAT3依赖性的乳腺癌细胞系的凋亡率。[1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9c2 MmK3SpVv[3Srb36gRZN{[Xl? NHzLTJQyOOLCid88US=> NWDaU|lFPOLCiXi= NWD1OHRjemW4ZYLz[ZMhfGinIHXm[oVkfHNib3[gTWwuOjd? NHHWVnMzPjN|OU[zNy=>
NPC  M13r[WZ2dmO2aX;uJGF{e2G7 MkXlNE04NjViwsXN NGmzblRi[m:uaYPo[ZMhTU2WLXzpb4UhdW:uZXP1cIFzKGGudHXyZZRqd26|LDDhcoQh[2WubDDtbYdz[XSrb36gZY5lKGmwdnHzbY9vKGmwZIXj[YQh[nliUlvJVEBsdm:la3Tve44> MY[yOVkyPTR|MB?=
HASMC M3P5Z2Z2dmO2aX;uJGF{e2G7 NEDNfYMyNjJ3LUWg{txO MljnNlAhdWmw M2PPcGROW00EoB?= NWLLfVNjcW6qaXLpeJMheC1qWTmtV3RCXC1zLEOsOUB{cWewYXzzxsA> M1\4NlI2QDR7NkKy
H9c2  MnLvSpVv[3Srb36gRZN{[Xl? M120d|IwOTBizszN NXL6dIlVOiCq NH3vUo9FVVORwrC= NUnO[FlS[WK{b3fheIV{yqC2aHWgZ5l1d3C{b4TlZ5RqfmViZX\m[YN1eyCxZjDJUE0zPyCjZ3HpcpN1KFOK NHnh[mwzPTh{MEmwOy=>
A431 NX\XenhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWyxsDPxE1? MYOyxsBp MkToZoxw[2u|IFXHSk1z\X[ncoPl[EBl\WO{ZXHz[ZMhcW5iY3XscEB3cWGkaXzpeJk> NGPiW|IzPTd{MESzOS=>
A431 MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TvdlLDqM7:TR?= NGr5UpUzyqCq NWnDbZh[cW6lcnXhd4V{KGmwIHHwc5B1d3OrczDpcoR2[2WmIHL5JJNpcWuxbnnu M2XrR|I2PzJyNEO1
SiHa M4O5eWNmdGxiVnnhZoltcXS7IFHzd4F6 NGO3OlQ2NTd3IH7N Ml;mNlTDqGkEoB?= M3;STJNpd3e|IH3vdpBpd2yxZ4mgc4Yh[SC2eYDpZ4FtKGGyb4D0c5Rq[yClZXzsJIFv\CCmb4PlMYRmeGWwZHXueEBtd3O|IH;mJINmdGxidnnhZoltcXS7wrC= NWP6XJNjOjV3M{m2OFQ>
SiHa NGCwO4pHfW6ldHnvckBCe3OjeR?= NELjcpU2NTd3IH7N MlTxNlTDqGkEoB?= MX3y[YR2[2W|IITo[eKheGixc4Doc5J6dGG2aX;uJIF1KHSqZTD0fZJwe2mwZTDy[ZNq\HWnIEewOeKh NISwXGMzPTV|OU[0OC=>
ECA109 NH3nO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETCVmgxNTJyIN88US=> Mn3YNlTDqGkEoB?= NEn5W3RKSzVyPUWuOVAh|ryP NYXpc3dFOjV2OUK0PFA>
TE13 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\jNE0zOCEQvF2= Ml;oNlTDqGkEoB?= MUPJR|UxRTZwMUZCpO69VQ>? NXTCeolFOjV2OUK0PFA>
KYSE150  NFT2SIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjoVmxzOC1{MDFOwG0> Ml3zNlTDqGkEoB?= MlnqTWM2OD1zMj62OOKh|ryP NWrTdWxDOjV2OUK0PFA>
ECA109 MnrTR4xwdm:pZX7pZ{BUfXK4aY\hcEBCe3OjeR?= NGTUdZIxNjYEoN88US=> MXSyOOKhcMLi NFjTfnJ{fXCycnXzd4V{KHSqZTDjcI9vd2enbnnjJIZwem2jdHnvci=> NEnOfI8zPTR7MkS4NC=>
TE13 MUHDcI9vd2enbnnjJHN2en[rdnHsJGF{e2G7 NUP2ZotyOC53wrFOwG0> NYn2W|l{OjUEoHlCpC=> MkP1d5VxeHKnc4Pld{B1cGViY3zvco9o\W6rYzDmc5Ju[XSrb36= MlXENlU1QTJ2OEC=
KYSE150  NW\6UZVES2yxbn;n[Y5q[yCVdYL2bZZidCCDc4PhfS=> NIja[IcxNjYEoN88US=> NWm5VVdGOjUEoHlCpC=> NGDQWXB{fXCycnXzd4V{KHSqZTDjcI9vd2enbnnjJIZwem2jdHnvci=> NH\ZTpgzPTR7MkS4NC=>
ECA109 Mnu0SpVv[3Srb36gRZN{[Xl? M4n5d|AvPcLizszN MYWyOOKhcMLi MULlcohidmOnczDJVk1qdmS3Y3XkJIdmdmW{YYTpc44hd2ZiRGPCdy=> NXryRYtVOjV2OUK0PFA>
PC3M-1E8 M1PUfGZ2dmO2aX;uJGF{e2G7 NGjKSlMzNjVxNT:xNEDPxE1? MVKwMVQhcA>? MYXpcohq[mm2czD0bIUhW1SDVEOgZYN1cX[jdHnvckBqdiCjIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>? NEjkUGIzPTJ4MUO2OS=>
PC3M-1E8 Mmm2SpVv[3Srb36gRZN{[Xl? MlXvNVAh|ryP NFrXUnczPCCq M17wU4Rwf26{ZXf1cIF1\XNiQnPsMZhNNCC|dYL2bZZqdiCjbnSgZ{1OgWN? NV\tNZRSOjV{NkGzOlU>
PC3M-1E8 MUTGeY5kfGmxbjDBd5NigQ>? MXOxNEDPxE1? NIXldYszPCCq MoL3bY5pcWKrdIOgTWwuPiCrbnT1Z4VlKFOWQWSzJIFkfGm4YYTpc44h[W6mIITo[UBKVC14LXnu[JVk\WRiU2TBWFMh[WO2aY\heIlwdg>? NUjXWWVlOjV{NkGzOlU>
PC3M-1E8 MYfDcI9vd2enbnnjJHN2en[rdnHsJGF{e2G7 MXOyMlUwPS9zMDFOwG0> NYn6O4ZGcW6qaXLpeJPDqHSqZTDjc4xwdnliZn;ycYF1cW:wIIPp[45q\mmlYX70cJk> M2fEb|I2OjZzM{[1
MDA-MB-231 MlHqSpVv[3Srb36gRZN{[Xl? NUHqdFlXOjBizszN MnTTNkBp M1nSfYV5cGmkaYTzJHNv[WmuIHHu[EBGNWOjZHjldolvKGW6cILld5Nqd25? NXvSdW5GOjVzNUOzOFk>
H9c2 NYX4d2NTTnWwY4Tpc44hSXO|YYm= MlTzNlAhyrWP M1vEc|MxKG2rbh?= MoPxSG1UV8Li MVjhZo9tcXOqZYOgdJJweG:ob3ytbY5lfWOnZDDBT3QheGixc4Doc5J6dGG2aX;uJIF1KGKxdHigd4VzPDd|IHHu[EB1cHJ|MEi= Mn6yNlUyODVyNke=
HaCaT  NYW3T5ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjuNGoyOCEEtV2= MYiyNEBucW5? M2nId2ROW00EoB?= NUK0UmJQ\W6qYX7j[ZMhe2:{YX\lcoljNSCjbnSgd5VvcXSrbnniMYlv\HWlZXSg[5Jwf3SqIHnubIljcXSrb36= MVyyOVAyOzlyNx?=
Caki-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnvbVFGOTBiwsXN Mm\HNlAhdWmw NEfZfHFFVVORwrC= MXvlcohidmOnczDzc5Ji\mWwaXKtJIFv\CC|dX7peIlvcWJvaX7keYNm\CCpcn;3eIghcW6qaXLpeIlwdg>? NVGxfYN3OjVyMUO5NFc>
HaCaT  MWTBdI9xfG:|aYOgRZN{[Xl? M1m1fVExKML3TR?= M1;JUlIxKG2rbh?= M13yUGROW00EoB?= NGDQ[GZqdmO{ZXHz[ZMheHKxcH;yeIlwdnNib3[gZZBweHSxdHnjJINmdGy|IHT1[UB1dyC2cnXheI1mdnRid3n0bEB{d3KjZnXubYIhd3Jic4XubZRqdmmk MoXPNlUxOTN7MEe=
FHL-primed hNSCs MmjJR4VtdCCYaXHibYxqfHliQYPzZZk> NIfTS5kxNjB{LUWg{txO MX63NkBp M3PQOIxm[WS|IITvJJRp\SCub4PzJI9nKGOnbHygeoli[mmuaYT5JIF1KGirZ3igZ49v[2WwdILheIlwdg>? NE\sNpUzPDl2NUSzOC=>
ELL-primed hNSCs NV3T[Wk5S2WubDDWbYFjcWyrdImgRZN{[Xl? MlrPNE4xOi13IN88US=> Mnj1O|IhcA>? NV7vUGJ6dGWjZIOgeI8hfGinIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJkh[XRiaHnnbEBkd26lZX70doF1cW:w M33zU|I1QTR3NEO0
SS MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlXZNU0yOCEQvF2= NHnqeIg4OiCq M{Pze2ROW09? NXHrSGN3[2G3c3XzJIEh\G:|ZT3k[ZBmdmSnboSgbY5pcWKrdHnvckBw\iC2aHWgeoli[mmuaYT5xsA> M1vxTVI1PzV4MUGx
SeAx  NInHWoZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1rEPVEuOTBizszN MV[3NkBp NXvaWI1PTE2VTx?= NXPuZ4xS[2G3c3XzJIEh\G:|ZT3k[ZBmdmSnboSgbY5pcWKrdHnvckBw\iC2aHWgeoli[mmuaYT5xsA> NILSRmEzPDd3NkGxNS=>
HuT-78 MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWOxMVExKM7:TR?= NHHIb5A4OiCq NFTF[2VFVVOR Mm\wZ4F2e2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7obYJqfGmxbjDv[kB1cGVidnnhZoltcXS7wrC= NHrKboYzPDd3NkGxNS=>
CD4+ NW[4V3VLSXCxcITvd4l{KEG|c3H5 NH33b3MyOOLCid88cS=> NY\vW3EyOjRiaB?= NXXUcFVqTE2VTx?= M3jpb4lv\HWlZYOgZZBweHSxc3nzJJN1em:wZ3z5 NUjZNYRlOjR5NU[xNVE>
MCF-7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfQNE41PjlvMz63OUDPxE1? MnjKOUBl MXvy[YR2[2W|IHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NWWyRlhPOjR5MkiwO|g>
MCF-7/LCC1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvIPIIzOC52NkmtN{44PSEQvF2= MVi1JIQ> NHizWZhz\WS3Y3XzJINmdGxiboXtZoVzKHOrZ37p[olk[W62bIm= MV6yOFczQDB5OB?=
MCF-7/LCC9 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O4ZVAvPDZ7LUOuO|Uh|ryP MVi1JIQ> M2TIW5Jm\HWlZYOgZ4VtdCCwdX3i[ZIhe2mpbnnmbYNidnSueR?= MVGyOFczQDB5OB?=
HaCaT M{LCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOxNEDDvU1? MYOyNEBucW5? NUPONZFDTE2VT9Mg MkPL[Y5p[W6lZYOg[ZZmem:uaX31d{1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? NEnwTWYzPDR{M{GzNS=>
HaCaT M1XNTmFxd3C2b4Ppd{BCe3OjeR?= MV[xNEDDvU1? NV3tZ285OjBibXnu M3HmWmROW00EoB?= M3O2c4VvcGGwY3XzJJRp\SCjcH;weI91cWNiZX\m[YN1eyCxZjDleoVzd2yrbYXz MUKyOFQzOzF|MR?=
MDA-MB-231 NX;sb4cyTnWwY4Tpc44hSXO|YYm= M2DwT|ExKML3TR?= M2PmblI1KGh? NUjsZpk6TE2VT9Mg M1PVN5Jm\HWlZYOgVE1UXEGWMzDlfJBz\XO|aX;u MoPrNlQ{PzZ3OE[=
SUM-159 MVTGeY5kfGmxbjDBd5NigQ>? NUL4NYcyOTBiwsXN MmXyNlQhcA>? MnPWSG1UV8Li MWjy[YR2[2W|IGCtV3RCXDNiZYjwdoV{e2mxbh?= MVSyOFM4PjV6Nh?=
SK-BR-3 M2HyeWZ2dmO2aX;uJGF{e2G7 Ml;QNVAhyrWP NUDtbHRFOjRiaB?= NEHGWoJFVVORwrC= NHW3dVRz\WS3Y3XzJHAuW1SDVEOg[ZhxemW|c3nvci=> NHrq[|czPDN5NkW4Oi=>
MCF7-HER2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWwMVExKM7:TR?= NUPOdGpiPDhiaB?= NXPCNYlOTE2VTx?= NYK2SHdicW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> M3nmVFI1Ojl5NUC4
MCF7-HER2 MnjTSpVv[3Srb36gRZN{[Xl? MXW1JO69VQ>? M2P0dVI1KGh? Mkf0SG1UVw>? NV:1Z5dp\GmvaX7pd4hmeyCVb4itNkwhV2O2LUSsJIFv\CC|bIXnJIV5eHKnc4Ppc44> NELpPJYzPDJ7N{WwPC=>
MCF7-HER2 MVzGeY5kfGmxbjDBd5NigQ>? M1\iTVUh|ryP NEHHTFkzPCCq NWO1W5o{TE2VTx?= Ml3m[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDFUXQhdWG{a3Xyd{whfmmvZX70bY4h[W6mIIPseYc> NEe5N3UzPDJ7N{WwPC=>
MCF7-HER2 NWrmNGp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nsVlUh|ryP MYqyOEBp MVTEUXNQ NIXGS|FmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHPvcYJqdmWmIIfpeIghUGW{Y3XweIlv MoTrNlQzQTd3MEi=
HMECs  MVHGeY5kfGmxbjDBd5NigQ>? NXjFW5A1OTBizszN Mn3aNkBp NWPEPGpUcW6qaXLpeJMhUU[QzsJCpI1m\GmjdHXkJJBpd3OyaH;yfYxifGmxbjDv[kBUXEGWMTygV3RCXDJiYX7kJHNVSVR| MmrHNlQzOTF|Mke=
HTR8/SVneo NEnvd3dHfW6ldHnvckBCe3OjeR?= Mn7qNeKh|ryPwrC= NFPiSWYyyqCq MV;zeZBxemW|c3XkJG9UVS2rbnT1Z4VlKFOWQWSzJJBpd3OyaH;yfYxifGmxbh?= NYTlPXhYOjRyNkCyOFE>
HTR8/SVneo MnfESpVv[3Srb36gRZN{[Xl? MkLrNE42NzIEoN88UeKh MX20PEBp MnP0doV{fG:{ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckB{fXCycnXzd4VlKGK7IF;TUS=> MWOyOFA3ODJ2MR?=
HTR8/SVneo Mn\QSpVv[3Srb36gRZN{[Xl? NYrSTIF6OcLizszNxsA> NWG4WW1qPDhiaB?= NETsNmp{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDtbYdz[XSrb36gZpkhV1OPwrC= NV6xU4ZJOjRyNkCyOFE>
C13* M12zeWFxd3C2b4Ppd{BCe3OjeR?= MmHLNE0yOCEQvF2= NWDncHNEOjRxNEigbC=> M{jN[Ilv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy M2fnd|I{QTZ{NUW4
OV2008 M4HvXWFxd3C2b4Ppd{BCe3OjeR?= M2LUR|AuOTBizszN Mm\kNlQwPDhiaB?= M{PyfIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy M3;WTFI{QTZ{NUW4
C13* NYPUWJF5SXCxcITvd4l{KEG|c3H5 NGTmRpczPC92ODDo NFnNe2JmdmijbnPld{BkcXOybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NVnTVpVxOjN7NkK1OVg>
OV2008 NVr5bZcySXCxcITvd4l{KEG|c3H5 NWPYcIxoOjRxNEigbC=> NW\DWZNS\W6qYX7j[ZMh[2m|cHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ MWGyN|k3OjV3OB?=
W480  NH;WU5dHfW6ldHnvckBCe3OjeR?= MXeyMlUwOTBizszN NEDHUYk{OCCvaX6= MmruSG1UVw>? NYTQXFBpe2Wwc3n0bZpmeyClZXzsd{B1dyClaHXtc5Ji\GmxdHjldoFxgSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Ml;DNlM6OzR7N{K=
SW837 NUPLVZo4TnWwY4Tpc44hSXO|YYm= Mne1Nk42NzFyIN88US=> MV[zNEBucW5? NIDKWmZFVVOR M2X1cpNmdnOrdHn6[ZMh[2WubIOgeI8h[2inbX;yZYRqd3SqZYLhdJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MV6yN|k{PDl5Mh?=
T24 NXHOTmVETnWwY4Tpc44hSXO|YYm= NIWwWVgzNzFyL{KwJO69VQ>? Mmn4NlQhcA>? MYHjZZV{\XNiZH;z[U1l\XCnbnTlcpQhcW6qaXLpeIlwdiCxZjD0bIUhS1iFTEGyMYlv\HWlZXSgbY5kemWjc3Wgc4YhcW64YXTpcoch[2WubIO= NXS1Zmd7OjN3Mk[wO|k>
CNE1 NW\hN2lFTnWwY4Tpc44hSXO|YYm= NGLTPIozOCEEtV2= NIPOSlY1QCCq MkW5Zoxw[2u|IITo[UBKVC14IHnuZ5Jm[XOnZDDwbI9{eGixconsZZRqd25ib3[gV5RifDN? MYeyN|M5OjlzNB?=
CNE2 NIfJUYdHfW6ldHnvckBCe3OjeR?= MXyyNEDDvU1? NFywOIU1QCCq NVqxTlJw[myxY3vzJJRp\SCLTD22JIlv[3KnYYPl[EBxcG:|cHjvdplt[XSrb36gc4YhW3SjdEO= NGDoUZUzOzN6MkmxOC=>
HONE1 MWnGeY5kfGmxbjDBd5NigQ>? NXL2c2twOjBiwsXN MkPKOFghcA>? M1;PTIJtd2OtczD0bIUhUUxvNjDpcoNz\WG|ZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJHN1[XR| NHntb5MzOzN6MkmxOC=>
CNE1 NVzaZ4IxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHnO4lHPCEQvF2= M3jKR5Nq\26rZnnjZY51dHlicnXkeYNmeyClZXzsJJZq[WKrbHn0fS=> NFLTdmYzOzN6MkmxOC=>
CNE1 M1\jO2Z2dmO2aX;uJGF{e2G7 NYThOZU{OC1{MDFOwG0> NHmw[owxNTRiaB?= NHvTe2lqdmirYnn0d{BUfGG2MzDhZ5RqfmG2aX;uJIlvKGFiZH;z[U0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NVr4ZWlsOjN|OEK5NVQ>
CNE2 NUPINWFQTnWwY4Tpc44hSXO|YYm= NIDXe|MxNTJyIN88US=> NIj5T4IxNTRiaB?= M1;kXYlvcGmkaYTzJHN1[XR|IHHjeIl3[XSrb36gbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy M{\kelI{Ozh{OUG0
HONE1 NHnTVItHfW6ldHnvckBCe3OjeR?= NHOyXowxNTJyIN88US=> Mk\QNE01KGh? NYDRNlhrcW6qaXLpeJMhW3SjdEOgZYN1cX[jdHnvckBqdiCjIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NE\ONZQzOzN6MkmxOC=>
CNE1 NUfNSo9{S2WubDDWbYFjcWyrdImgRZN{[Xl? MkXyNE42NTZ2IN88US=> NX3VUmJUPDhiaB?= NWnLZ|Vve3WycILld5NmeyClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MVGyN|M5OjlzNB?=
CNE2 MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkPCNE42NTZ2IN88US=> M1y1VlQ5KGh? MnPRd5VxeHKnc4Pld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M2PqfFI{Ozh{OUG0
HONE1 MlXNR4VtdCCYaXHibYxqfHliQYPzZZk> M3S5d|AvPS14NDFOwG0> Ml7iOFghcA>? MYPzeZBxemW|c3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NFfYdYEzOzN6MkmxOC=>
C666-1  MnfPR4VtdCCYaXHibYxqfHliQYPzZZk> MoXtNE42NTZ2IN88US=> MmHsOFghcA>? NXfLW2J7e3WycILld5NmeyClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MUCyN|M5OjlzNB?=
CNE1 NELTW3lCeG:ydH;zbZMhSXO|YYm= MV[xNEDDvU4EoB?= M3nNfFQ5KGh? NF;kc|ZqdmS3Y3XzJIFxd3C2b4Ppd:Kh MWWyN|M5OjlzNB?=
CNE2 MV\BdI9xfG:|aYOgRZN{[Xl? MnyxNVAhyrWPwrC= MoLlOFghcA>? Mn7pbY5lfWOnczDhdI9xfG:|aYRCpC=> MXqyN|M5OjlzNB?=
HONE1 NVT6SI9sSXCxcITvd4l{KEG|c3H5 NVHvcJhqOTBiwsXNxsA> MnrrOFghcA>? MoHlbY5lfWOnczDhdI9xfG:|aYRCpC=> M4\zPFI{Ozh{OUG0
CNE2 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUC1SGlFOS9{IN88US=> NHzDcGw1QCCq MUDz[Y5{cXSrenWgZ4VtdHNidH:gdoFlcW:2aHXyZZB6 MWqyN|M5OjlzNB?=
HONE1 NVr3VlVQS2WubDDWbYFjcWyrdImgRZN{[Xl? MkfiNU8zKM7:TR?= MVe0PEBp NWixSlhVe2Wwc3n0bZpmKGOnbHzzJJRwKHKjZHnveIhmemGyeR?= M2jpdFI{Ozh{OUG0
C666-1  M{fhRWNmdGxiVnnhZoltcXS7IFHzd4F6 NGHnT5UyNzJizszN NF\RN5Q1QCCq Mmi5d4Vve2m2aYrlJINmdGy|IITvJJJi\GmxdHjldoFxgQ>? MWeyN|M5OjlzNB?=
HEC-1A NWPqSoExTnWwY4Tpc44hSXO|YYm= MnvmNeKh|ryPwrC= MUGyOEBp MlPUSG1UVw>? NXfDb3I4[myxY3vzJJRp\SCPVVOyNE1mdmijbnPl[EBqdn[jc3nvckB1emmpZ3Xy[YQh[nliMUClJGZDWw>? NVH2NHVoOjN{NkKyNFg>
RL95-2 MYDGeY5kfGmxbjDBd5NigQ>? NWfyVoxKOcLizszNxsA> NEf0OZgzPCCq M3XSeGROW09? M4TMVYJtd2OtczD0bIUhVVWFMkCt[Y5p[W6lZXSgbY53[XOrb36geJJq\2encnXkJIJ6KDFyJTDGRnM> M1nGZlI{OjZ{MkC4
HEC-1A MWjGeY5kfGmxbjDBd5NigQ>? NYHjRYk6OcLizszNxsA> MUWyOEBp MWHEUXNQ MV\icI9kc3NidHjlJG1WSzJyLXXubIFv[2WmIHnueoF{cW:wIITybYdo\XKnZDDifUBGT0cEoB?= NHnJPWwzOzJ4MkKwPC=>
RL95-2 NHTQRmJHfW6ldHnvckBCe3OjeR?= NEDBdVIyyqEQvF5CpC=> M17EV|I1KGh? NGjvZoRFVVOR MUXicI9kc3NidHjlJG1WSzJyLXXubIFv[2WmIHnueoF{cW:wIITybYdo\XKnZDDifUBGT0cEoB?= MmjKNlMzPjJ{MEi=
CT26 NWSzN4Y1TnWwY4Tpc44hSXO|YYm= NEjtTnUzOCCvTR?= NGXKPFkyKGh? MYDzeZBxemW|c3XzJGhITi2rbnT1Z4VlKF[HR1[g[ZhxemW|c3nvcuKh MXSyN|I{OzF4Mx?=
UM-SCC-17B NWrJZZl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHyxOXNKSzVyPUKuOVYzKMLzIECuOFA6KM7:TTygS2k2OD1zLkK3PUDDuSByLkG5OEDPxE1? NXzDPYJIOjJ5N{C4PVk>
OSC-19 NWP0e3VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e0XGlEPTB;Mz60PFEhyrFiMD65OVMh|ryPLDDHTVUxRTFwM{[2JOKyKDBwN{ewJO69VQ>? MYKyNlc4ODh7OR?=
Cal33 Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jHPWlEPTB;Mj6yPFIhyrFiMD60NlMh|ryPLDDHTVUxRTFwM{S5JOKyKDBwM{[zJO69VQ>? NXm3S|J4OjJ5N{C4PVk>
UM-SCC-22B MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L5dWlEPTB;Mj62OFghyrFiMD61OFIh|ryPLDDHTVUxRTFwM{KwJOKyKDBwMkC0JO69VQ>? NHz4U40zOjd5MEi5PS=>
UM-SCC-17B NFXETpJHfW6ldHnvckBCe3OjeR?= NU\0OnRWOC1|MDFOwG0> Ml65NE0zPCCq NGG4e5VqdmirYnn0d{BUXEGWMzDhZ5RqfmG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NYDjZVlrOjJ5N{C4PVk>
OSC-19 Ml3JSpVv[3Srb36gRZN{[Xl? NFX4[GsxNTNyIN88US=> M3m5bVAuOjRiaB?= NYW0OlQ1cW6qaXLpeJMhW1SDVEOgZYN1cX[jdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 NVzNUnp4OjJ5N{C4PVk>
Cal33 MX3GeY5kfGmxbjDBd5NigQ>? MYOwMVMxKM7:TR?= NHq2clUxNTJ2IHi= M3XYeYlvcGmkaYTzJHNVSVR|IHHjeIl3[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NELNOYkzOjd5MEi5PS=>
UM-SCC-22B MVPGeY5kfGmxbjDBd5NigQ>? NHPIdpUxNTNyIN88US=> NGXzWWsxNTJ2IHi= MXPpcohq[mm2czDTWGFVOyCjY4TpeoF1cW:wIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? NGLG[lAzOjd5MEi5PS=>
U-87MG NVnZZndIS2WubDDWbYFjcWyrdImgRZN{[Xl? NIm5Z2kxNTFyIN88US=> NGPCeFA4OiCq MUfEUXNQ Mn;LbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? Mm\QNlU1OzZ4OEK=
U-373MG MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4PlO|AuOTBizszN MoniO|IhcA>? MXTEUXNQ MnGzbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MWSyOVQ{PjZ6Mh?=
SH-SY5Y MkT0R4VtdCCYaXHibYxqfHliQYPzZZk> MXiwMVExKM7:TR?= MYO3NkBp MkjDSG1UVw>? M1rGVolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NHfIVIYzPTR|Nk[4Ni=>
Tu-9648 MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXrxNWF[OC1zMDFOwG0> MljnO|IhcA>? MnnISG1UVw>? M1WzWIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MnXLNlU1OzZ4OEK=
Neuro-2a MlXTR4VtdCCYaXHibYxqfHliQYPzZZk> Ml;yNE0yOCEQvF2= NHPsbWc4OiCq MlL4SG1UVw>? MnvTbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? Mn;ZNlU1OzZ4OEK=
PCNs MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHfGd4IxNTFyIN88US=> MWK3NkBp MXXEUXNQ NVe1eph4cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M1zuUFI2PDN4Nkiy
PGCs NXTifolTS2WubDDWbYFjcWyrdImgRZN{[Xl? NF;U[44xNTFyIN88US=> NVH3eIV[PzJiaB?= M{HSWWROW09? NU[3fIhUcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MYSyOVQ{PjZ6Mh?=
RAW264.7 MmPMSpVv[3Srb36gRZN{[Xl? MkG4NVAh|ryP NWXCVFJpOTJiaB?= NInhNW9i[nKxZ3H0[ZMhfGinIH3SUmEh\XiycnXzd4lwdnNib3[gTmFMOixiU2TBWFEtKFOWQWSyMEBidmRiU2TBWFMhcW6mdXPl[EBjgSCGT16gZY5lKFRvMjD0c5hqdg>? NF61ZYszOjR3NESzNS=>
RAW264.7 NVe0RVY4SXCxcITvd4l{KEG|c3H5 Mof1OU8yOCEQvF2= NIr6dVM1PSCvaX6= MW\lcohidmOnczD0c5hqdnNiaX7keYNm\CCjcH;weI9{cXNiYX7kJG1OWCCub4Pz MoP6NlI1PTR2M{G=
SW480 NHPtUI9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWPzWWZJPS9zMD:yNEDPxE1? M2X4elczKGh? MVnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCxZjD0bIUhSUyGSDuvR2QyOzNtwrDj[Yxtew>? NHS2c4MzOTlyMEO5Oy=>
HCT116 MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mny2OU8yOC9{MDFOwG0> MlzZO|IhcA>? M4OwVYlvcGmkaYTzJINmdGxidnnhZoltcXS7IH;mJJRp\SCDTFTIL{9ETDF|MzxCpINmdGy| MVKyNVkxODN7Nx?=
DLD-1  MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXXINpRvPS9zMD:yNEDPxE1? NHzVTZE4OiCq MluybY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlib3[geIhmKEGORFirM2NFOTN|K9MgZ4VtdHN? M1zjW|IyQTByM{m3
SNU387  MofKR4VtdCCYaXHibYxqfHliQYPzZZk> MUeyNOKh|ryPwrC= NHrQWYszPCCq NYnDfWFDemWmdXPld{Bk\WyuII\pZYJqdGm2eR?= MnjINlE{OTF7N{W=
SNU398 NGPBPWRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIHZU|QzOMLizszNxsA> NXLP[FVNOjRiaB?= MnuxdoVlfWOnczDj[YxtKH[rYXLpcIl1gQ>? MkjMNlE{OTF7N{W=
HepG2 NEXOOHlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHzEU5czOMLizszNxsA> NET3cFEzPCCq NFKydoFz\WS3Y3XzJINmdGxidnnhZoltcXS7 NXHwT4VSOjF|MUG5O|U>
Huh-7 M3m1VGNmdGxiVnnhZoltcXS7IFHzd4F6 NHLNUIczOMLizszNxsA> NU\sO49POjRiaB?= MWry[YR2[2W|IHPlcIwhfmmjYnnsbZR6 M4XzSlIyOzFzOUe1
VSMC NYDtXHMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFftXJU{NzVxMUCg{txO NU\FNZNuOzBibXnu MYjEUXNQ MX3wdoV3\W62czDQSGdHNSCjbnSgeIhzd22kaX6tcYVlcWG2ZXSgWnNOSyCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NX7QVmd5OjB6NEezNFY>
MDA-MB-231 NWHvUW9FSXCxcITvd4l{KEG|c3H5 MWCxNEDPxE1? M4Tpc|I1KGh? M1q4Z2ROW00EoB?= NWfkeppHcW6mdXPld{BieG:ydH;zbZM> M1XJW|E4OTF2MEC1
MDA-MB-435S MkXGRZBweHSxc3nzJGF{e2G7 M4Dwd|ExKM7:TR?= NEP0PIszPCCq NEjPSFFFVVORwrC= MmjCbY5lfWOnczDhdI9xfG:|aYO= MXexO|EyPDByNR?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-STAT3 / STAT3 ; 

PubMed: 25261365     


(A) PC3M-1E8 cells were treated with different doses of Stattic for 4 h. (B) PC3M-1E8 cells were treated with 10 μM Stattic for different time points. 

Survivin / c-Myc / Bcl-xl ; 

PubMed: 25261365     


Western blot analysis of STAT3 downstream targets in PC3M-1E8 cells treated with 10 μM Stattic for 24 h. 

PARP / C-PARP / Caspase-3 / C-Caspse-3 ; 

PubMed: 23382914     


NPC cells were exposed to the indicated concentrations of Stattic for 48 h; apoptotic cells were measured by western blot analysis of cleaved PARP and cleaved caspase-3. Protein levels were quantified using ImageJ software. 

25261365 23382914
Immunofluorescence
p-STAT3 / STAT3 / Survivin ; 

PubMed: 25261365     


Cellular localization of pSTAT3 and survivin (green) was observed by confocal microscopy after immunofluorescent staining of PC3M-1E8 cancer cells treated with 10 μM Stattic.

25261365
Growth inhibition assay
Cell viability; 

PubMed: 23382914     


Stattic inhibits the cell viability of NPC cells in a time-dependent manner. CNE2 cells were treated with 8 µM Stattic for the indicated times, and cell viability was measured by the MTT assay. 

23382914
ELISA
BDNF; 

PubMed: 27456333     


BDNF secretion was analyzed using ELISA in A549 and H1299 cells treated with or without Stattic. Results are shown as the mean ± S.E. n = 3; *p < 0.05, vs Control group, Student’s t-test. 

27456333

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：

[1]
- 合并

高通量筛选和荧光偏振检测:

在约30°C下进行筛选。通过实验化合物与STAT1, STAT5, 和 Lck 的SH2结构域结合的类似实验验证筛选的特异性。所有FP实验的Buffer组分的终浓度为10 mM HEPES(pH 7.5),1 mM EDTA,0.1% Nonidet P-40,50 mM NaCl,和10% DMSO。二硫苏糖醇的存在对抑制活性是必不可少的。肽序列为:STAT3,5-carboxyfluorescein-GY(PO3H2)LPQTV-NH2; STAT1, 5-carboxyfluorescein-GY(PO3H2)DKPHVL;STAT5, 5-carboxyfluorescein-GY(PO3H2)LVLDKW; 和 Lck, 5-carboxyfluorescein-GY(PO3H2)EEIP。在 30°C下进行特异性分析, 使用150 nM蛋白(STAT1,STAT3,和STAT5)。在37°C下进行分析，使用370 nM 蛋白(STAT3)或100 nM蛋白 (Lck)。蛋白与实验化合物在Eppendorf管中在指定温度环境下温育60分钟，然后加入相应的5-carboxyfluorescein标记的肽（终浓度为10 nM）。混合物至少平衡30分钟，然后在室温下测量。实验化合物在20×stock在DMSO中稀释到指定浓度。使用 SigmaPlot绘制结合曲线和抑制曲线。独立实验中，所有竞争曲线都需重复三次。
细胞实验：

[2]
- 合并
  • Cell lines: Ly3细胞
  • Concentrations: ~2.5 μM
  • Incubation Time: 48小时
  • Method:

    MTS


    (Only for Reference)
动物实验：

[2]
- 合并
  • Animal Models: Ly3亲本NOD/SCID IL2R移植瘤
  • Dosages: 每天3.75 mg/kg
  • Administration: 瘤内注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 42 mg/mL (198.87 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O
 10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 211.19
化学式

C8H5NO4S
CAS号 19983-44-9
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    We need to dissolve the compound for i.p. injection, could you give me some suggestions?

  • 回答：

    S7024 Stattic can be dissolved in 2% DMSO/PEG 300/dd H2O at 8 mg/mL as a clear solution.

Selleck产品目录册

STAT Signaling Pathway Map

相关STAT产品

  • Cerdulatinib (PRT062070) New

    Cerdulatinib (PRT-062070)是一种具有口服活性的多靶点酪氨酸激酶抑制剂，对JAK1/JAK2/JAK3/TYK2和Syk的IC50分别为12 nM/6 nM/8 nM/0.5 nM和32 nM。也能够抑制测试的其他19种激酶，IC50均低于200 nM。

  • FLLL32 New

    FLLL32 是一种有效的 JAK2/STAT3 抑制剂，IC50 <5 μM。FLLL32 在乳腺癌细胞中通过 IFNα 和 IL-6 来抑制STAT3磷酸化的诱导。

  • S3I-201

    S3I-201 (NSC 74859) 有效抑制STAT3的DNA结合活性，IC50为86 μM，而对STAT1和STAT5的抑制活性低。

    Features:S3I-201是化学探测器抑制剂，可以除去乳腺瘤。

  • Fludarabine

    Fludarabine (FaraA, Fludarabinum)在血管平滑肌细胞中是一种STAT1活化抑制剂，特异性降低STAT1蛋白质水平（和mRNA水平） ，而对其他STATs无此作用。它还是一种DNA合成抑制剂。Fludarabine可诱导凋亡。

  • Cryptotanshinone

    Cryptotanshinone 是一种STAT3抑制剂，无细胞试验中IC50为4.6 μM，强烈抑制STAT3 Tyr705磷酸化，对STAT3 Ser727作用效果弱，对STAT1和STAT5没有作用效果。Cryptotanshinone 可诱导ROS依赖的自噬和线粒体介导的凋亡。

    Features:Cryptotanshinone 通过选择性抑制STAT3 活性，而具有抗肿瘤活性。

  • Niclosamide

    Niclosamide (Niclocide)能够抑制DNA复制，并抑制STAT3，无细胞试验中IC50为0.7 μM。 Niclosamide 选择性地抑制STAT3的磷酸化，对其他同系物如STAT1和STAT5的激活没有明显抑制作用。

  • Nifuroxazide

    Nifuroxazide是可渗透细胞的，口服有效的硝基呋喃类止泻药，有效地抑制细胞内STAT1/3/5转录活性的激活，IC50为3 µM。

  • HO-3867

    HO-3867, 姜黄素的一种类似物, 是选择性的STAT3抑制剂。抑制STAT3的磷酸化、转录和DNA结合活性，而不影响其他活性STATs的表达。HO-3867 可诱导凋亡。

  • SH-4-54

    SH-4-54是一种高效的STAT抑制剂，其作用STAT3和STAT5的KD分别为300 nM和464 nM。

Tags: 购买Stattic | Stattic供应商 | 采购Stattic | Stattic价格 | Stattic生产 | 订购Stattic | Stattic代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID